Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002105 · ClinicalTrials.gov registry record · Phase 3
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
A Phase 3 study of HIV Infections and Sarcoma, Kaposi, sponsored by Sequus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
- 4
- Study locations
NCT00002105: Completed Phase 3 study of HIV Infections and Sarcoma, Kaposi, sponsored by Sequus Pharmaceuticals.
NCT00002105 is a Phase 3 study of HIV Infections and Sarcoma, Kaposi that has completed, run by Sequus Pharmaceuticals. The registered enrollment target is 220 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (51% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002105, a Phase 3 study of HIV Infections and Sarcoma, Kaposi, has completed, sponsored by Sequus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
- 4
- Study locations
Study Summary
To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of DOX-SL compared to BV in a population of AIDS patients with moderate to severe KS.
Conditions Studied
Interventions
- DRUG Doxorubicin hydrochloride (liposomal)
- DRUG Bleomycin sulfate
- DRUG Vincristine sulfate
Study Locations (4)
Massachusetts
- Beth Israel Hosp - Boston
New York
- Mount Sinai Med Ctr - New York
Texas
- Twelve Oaks Hosp - Houston
Washington
- Virginia Mason Research Center / Clinical Trial Unit - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002105
The ClinicalTrials.gov registry entry for NCT00002105 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (51% lower). The listed sponsor is Sequus Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Doxorubicin hydrochloride (liposomal) is the first listed.
NCT00002105 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00002105 about?
NCT00002105 is a clinical study titled "Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma". To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of DOX-SL compared to BV in a popula...
What is the current status of trial NCT00002105?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants.
What conditions does trial NCT00002105 study?
This clinical trial studies the following conditions: HIV Infections, Sarcoma, Kaposi.
What interventions are being tested in trial NCT00002105?
The interventions under investigation include: Doxorubicin hydrochloride (liposomal) (DRUG), Bleomycin sulfate (DRUG), Vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00002105?
This trial is sponsored by Sequus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002105 being conducted?
This trial has 4 study locations across Massachusetts, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.